PHAR
Price:
$13.34
Market Cap:
$938.08M
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kin...[Read more]
Industry
Biotechnology
IPO Date
2020-12-23
Stock Exchange
NASDAQ
Ticker
PHAR
According to Pharming Group N.V.’s latest financial reports and current stock price. The company's current PE Ratio is 83.38. This represents a change of 539.78% compared to the average of 13.03 of the last 4 quarters.
The mean historical PE Ratio of Pharming Group N.V. over the last ten years is 37.36. The current 83.38 PE Ratio has changed 22.22% with respect to the historical average. Over the past ten years (40 quarters), PHAR's PE Ratio was at its highest in in the June 2023 quarter at 167.19. The PE Ratio was at its lowest in in the September 2021 quarter at -407.20.
Average
37.36
Median
24.47
Minimum
-80.47
Maximum
348.78
Discovering the peaks and valleys of Pharming Group N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 88.99%
Maximum Annual PE Ratio = 348.78
Minimum Annual Increase = -699.53%
Minimum Annual PE Ratio = -80.47
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 348.78 | -699.53% |
| 2024 | -58.18 | -27.70% |
| 2023 | -80.47 | -224.71% |
| 2022 | 64.52 | 88.99% |
| 2021 | 34.14 | 24.54% |
| 2020 | 27.41 | -9.06% |
| 2019 | 30.14 | 40.08% |
| 2018 | 21.52 | -364.37% |
| 2017 | -8.14 | 32.04% |
| 2016 | -6.16 | -52.43% |
The current PE Ratio of Pharming Group N.V. (PHAR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
70.05
5-year avg
61.76
10-year avg
37.36
Pharming Group N.V.’s PE Ratio is greater than Tango Therapeutics, Inc. (-37.92), greater than Septerna Inc (-46.10), greater than Arbutus Biopharma Corp (5.49), greater than Fortrea Holdings Inc. (-3.58), greater than ProKidney Corp. (-3.33), greater than Bicara Therapeutics Inc. Common Stock (-9.67), greater than Palvella Therapeutics, Inc. (-35.54), greater than Mind Medicine (MindMed) Inc. (-17.98), greater than Kura Oncology, Inc. (-3.25), greater than EyePoint Pharmaceuticals, Inc. (-3.90),
| Company | PE Ratio | Market cap |
|---|---|---|
| -37.92 | $3.92B | |
| -46.10 | $1.68B | |
| 5.49 | $904.72M | |
| -3.58 | $1.67B | |
| -3.33 | $615.34M | |
| -9.67 | $1.47B | |
| -35.54 | $1.75B | |
| -17.98 | $1.56B | |
| -3.25 | $967.64M | |
| -3.90 | $1.15B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pharming Group N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Pharming Group N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Pharming Group N.V.'s PE Ratio?
How is the PE Ratio calculated for Pharming Group N.V. (PHAR)?
What is the highest PE Ratio for Pharming Group N.V. (PHAR)?
What is the 3-year average PE Ratio for Pharming Group N.V. (PHAR)?
What is the 5-year average PE Ratio for Pharming Group N.V. (PHAR)?
How does the current PE Ratio for Pharming Group N.V. (PHAR) compare to its historical average?